What's New

Last Posted: May 09, 2019

• Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
  Elisei Rossella et al. Annales d'endocrinologie 2019 Apr
• Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer.
  Zhao Jingzhu et al. Oncology letters 2019 May 17(5) 4661-4666
• Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: A National Cohort Study.
  Høxbroe Michaelsen Sanne et al. Journal of surgical oncology 2019 May 119(6) 687-693
• Previously undescribed thyroid-specific miRNA sequences in papillary thyroid carcinoma.
  Barros-Filho Mateus Camargo et al. Journal of human genetics 2019 Mar
• Appropriate Management of Attenuated Familial Adenomatous Polyposis: Report of a Case and Review of the Literature.
  Sokic-Milutinovic Aleksandra et al. Digestive diseases (Basel, Switzerland) 2019 Mar 1-6
• Can current molecular tests help in the diagnosis of indeterminate thyroid nodule FNAB?
  Ferraz Carolina et al. Archives of endocrinology and metabolism 2018 62(6) 576-584
• Patient quality of life and prognosis in multiple endocrine neoplasia type 2.
  Grey Joanna et al. Endocrine-related cancer 2018 25(2) T69-T77
• Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes.
  Henn Jonas et al. Hereditary cancer in clinical practice 2019 175
• Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
  Mostoufi-Moab Sogol et al. Thyroid : official journal of the American Thyroid Association 2018 28(1) 60-67
• High-accuracy Detection of Preoperative Thyroid Nodules Using Combination of BRAF V600E Mutation and TMPRSS4 mRNA Level.
  Zhang Yanfang et al. Archives of medical research 2018 Dec
• Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.
  El Lakis Mustapha et al. Surgery 2018 Oct
• When should genetic testing be performed in patients with neuroendocrine tumours?
  O'Shea Triona et al. Reviews in endocrine & metabolic disorders 2017 18(4) 499-515
• Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
  Allin D M et al. European journal of cancer (Oxford, England : 1990) 2018 Sep 103165-175
• Management of Individuals at Increased Hereditary Risk
  ASCO, 2018
• Methylation markers differentiate thyroid cancer from benign nodules.
  Stephen J K et al. Journal of endocrinological investigation 2018 Feb 41(2) 163-170